Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments.

IF 2.7 3区医学 Q2 HEMATOLOGY

Current Hematologic Malignancy Reports Pub Date : 2021-08-01 DOI:10.1007/s11899-021-00635-3

Praveen Ramakrishnan Geethakumari, Dheepthi Perumal Ramasamy, Bhagirathbhai Dholaria, Jesús Berdeja, Ankit Kansagra

{"title":"Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments.","authors":"Praveen Ramakrishnan Geethakumari, Dheepthi Perumal Ramasamy, Bhagirathbhai Dholaria, Jesús Berdeja, Ankit Kansagra","doi":"10.1007/s11899-021-00635-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive.Recent findings: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive. This review article addresses the present-day challenges and discusses opportunities to optimize the access and affordability of the CAR T-cell therapy. The field of cellular immunotherapy is going to change the future of solid tumors and non-oncological diseases. However, this promising therapy poses challenges in the administration and management of quality in the current field of healthcare. We describe various novel approaches to manage challenges in improving access and improving widescale implementation of cellular therapies.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 4","pages":"345-356"},"PeriodicalIF":2.7000,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11899-021-00635-3","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11899-021-00635-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 16

Abstract

Purpose of review: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive.

Recent findings: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive. This review article addresses the present-day challenges and discusses opportunities to optimize the access and affordability of the CAR T-cell therapy. The field of cellular immunotherapy is going to change the future of solid tumors and non-oncological diseases. However, this promising therapy poses challenges in the administration and management of quality in the current field of healthcare. We describe various novel approaches to manage challenges in improving access and improving widescale implementation of cellular therapies.

Abstract Image

查看原文本刊更多论文

在提供新的细胞和免疫治疗过程中平衡质量、成本和可及性。

综述目的:嵌合抗原受体(CAR) t细胞疗法目前正在改变美国多种fda批准的细胞治疗产品的血液系统恶性肿瘤的景观。目前CAR - t细胞疗法的给药过程复杂、劳动密集且昂贵。嵌合抗原受体(CAR) t细胞疗法目前正在改变血液系统恶性肿瘤的景观，在美国有多种fda批准的细胞治疗产品。目前CAR - t细胞疗法的给药过程复杂、劳动密集且昂贵。这篇综述文章解决了当前的挑战，并讨论了优化CAR - t细胞治疗的可及性和可负担性的机会。细胞免疫治疗领域将改变实体瘤和非肿瘤疾病的未来。然而，这种有希望的治疗方法在当前医疗保健领域的行政和质量管理方面提出了挑战。我们描述了各种新的方法来管理挑战，以改善访问和改善细胞疗法的广泛实施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.